VERA News and Press, Vera Therapeutics Inc.

2024-05-09 10:38:59 ET More on Vera Therapeutics Vera Therapeutics: Waiting For A Pullback Top 10 best performing biotech stocks of 2024 so far Seeking Alpha’s Quant Rating on Vera Therapeutics Historical earnings data for Vera Therapeutics Fin...

Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatment Topline 96-week data from ORIGIN 2 trial expected in Q4 2024 Pivotal Phase 3 ORIGIN 3 trial estimated to complet...

BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,000 shares of Class A co...

2024-05-05 03:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-11 08:36:33 ET More on Alpine Immune Sciences Alpine Immune Sciences, Inc. (ALPN) Q4 2023 Earnings Call Transcript Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug Vertex enters into agreement to acquire Alpine Immune Sciences ...

2024-04-10 17:20:42 ET Gainers: Rallybio Corporation ( RLYB ) +42% . Alpine Immune Sciences ( ALPN ) +36% . Vera Therapeutics ( VERA ) +10% . Relay Therapeutics ( RLAY ) +7% . Olema Pharmaceuticals  ( OLMA ) +5% . Lose...

2024-04-10 12:41:07 ET More on Alpine Immune Sciences Alpine Immune Sciences, Inc. (ALPN) Q4 2023 Earnings Call Transcript Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug Alpine Immune Sciences Q4 2023 Earnings Preview Wolfe starts A...

2024-04-03 13:38:39 ET Summary The stock of Vera Therapeutics, Inc. has surged following positive trial data for its lead product candidate, atacicept. Atacicept could become a best-of-breed drug in the large IgAN space, but its potential launch is not until 2026 if all goes to sc...

72-week data of atacicept in IgAN accepted as a best-ranked abstract Analysis of impact of atacicept on hematuria in IgAN accepted as a focused oral presentation BRISBANE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotec...

2024-03-20 15:01:51 ET More on Vera Therapeutics Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect Top 10 best performing biotech stocks of 2024 so far Vera Therapeutics prices upsized stock offering to raise $250 million Seeking A...